CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$0.95 USD
-0.03 (-2.86%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.95 0.00 (-0.37%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CARM 0.95 -0.03(-2.86%)
Will CARM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CARM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CARM
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
CARM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
Other News for CARM
Catalyst Watch: Tesla deliveries, Nike earnings, port strike threat and the jobs report
Successful Completion of Tender Offer on Carmila?s Bonds With ?200,100,000 of Bonds Tendered
Carmila Successfully Issues Inaugural ?300M 7-Year Green Bond, Paying a Fixed Annual Coupon of 3.875%
Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes
Carisma Therapeutics and Moderna expand collaboration to develop CAR-M therapies